|
KR100942863B1
(ko)
*
|
1999-08-24 |
2010-02-17 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
|
US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
TWI335336B
(es)
|
2000-02-10 |
2011-01-01 |
Abbott Gmbh & Co Kg |
|
|
WO2002051438A2
(en)
|
2000-12-22 |
2002-07-04 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
PE20020801A1
(es)
|
2001-01-05 |
2002-09-06 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
|
GEP20074091B
(en)
|
2001-04-26 |
2007-04-25 |
Biogen Idec Inc |
Cripto blocking antibodies and uses thereof
|
|
EP1463522A4
(en)
|
2001-05-16 |
2005-04-13 |
Einstein Coll Med |
HUMAN ANTI-PNEUMOCOCCAL ANTIBODIES FROM NON-HUMAN ANIMALS
|
|
IL149701A0
(en)
*
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
|
MXPA04000134A
(es)
*
|
2001-06-26 |
2005-06-06 |
Abgenix Inc |
Anticuerpos para ligandos de osteoprotegerina.
|
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
SI1527100T1
(sl)
|
2002-03-29 |
2009-12-31 |
Schering Corp |
Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
|
|
AU2003234736B2
(en)
|
2002-04-12 |
2008-09-25 |
E. R. Squibb & Sons, L.L.C. |
Methods of treatment using CTLA-4 antibodies
|
|
WO2004029069A2
(en)
*
|
2002-09-30 |
2004-04-08 |
Pfizer Products Inc. |
Hybridomas producing high levels of human sequence antibody
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
CA2535859A1
(en)
*
|
2003-08-14 |
2005-03-03 |
Dyax Corp. |
Endotheliase-2 ligands
|
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
|
MX370489B
(es)
|
2004-01-09 |
2019-12-16 |
Pfizer |
Anticuerpos contra madcam.
|
|
CA2560919A1
(en)
*
|
2004-03-26 |
2005-10-06 |
Pfizer Products Inc. |
Uses of anti-ctla-4 antibodies
|
|
US7494779B2
(en)
|
2004-06-14 |
2009-02-24 |
Li-Te Chin |
Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
|
|
AU2005259221B2
(en)
|
2004-07-01 |
2011-02-10 |
Innate Pharma |
Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
|
|
KR20080019733A
(ko)
|
2004-07-16 |
2008-03-04 |
화이자 프로덕츠 인코포레이티드 |
항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
|
|
US7892827B2
(en)
|
2004-11-26 |
2011-02-22 |
Pieris Ag |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
NZ560844A
(en)
|
2005-03-08 |
2008-08-29 |
Pharmacia & Upjohn Co Llc |
Anti-MAdCAM antibody compositions
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
|
KR20070108259A
(ko)
*
|
2005-03-23 |
2007-11-08 |
화이자 프로덕츠 인크. |
Ｃｔｌａ-4 항체와 호르몬 요법에 의한 전립선암의 치료법
|
|
US7812135B2
(en)
|
2005-03-25 |
2010-10-12 |
Tolerrx, Inc. |
GITR-binding antibodies
|
|
EA201100642A1
(ru)
|
2005-04-25 |
2011-12-30 |
Пфайзер Инк. |
Антитела к миостатину
|
|
MX2007013304A
(es)
|
2005-04-26 |
2007-12-13 |
Pfizer |
Anticuerpos de p-caderina.
|
|
US20090041783A1
(en)
|
2005-04-28 |
2009-02-12 |
Mochida Pharmaceutical Co., Ltd. |
Anti-platelet membrane glycoprotein vi monoclonal antibody
|
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質ｖｉモノクローナル抗体
|
|
NZ563193A
(en)
|
2005-05-09 |
2010-05-28 |
Ono Pharmaceutical Co |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
US8652465B2
(en)
|
2005-06-08 |
2014-02-18 |
Emory University |
Methods and compositions for the treatment of persistent infections
|
|
NZ565311A
(en)
*
|
2005-07-07 |
2009-10-30 |
Pfizer |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
|
CN100443503C
(zh)
*
|
2005-07-18 |
2008-12-17 |
四川大学华西医院 |
人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
|
|
WO2007024715A2
(en)
|
2005-08-19 |
2007-03-01 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
|
EP2500354A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
PL2447283T3
(pl)
|
2005-09-07 |
2015-12-31 |
Amgen Fremont Inc |
Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1)
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
CA2624562A1
(en)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
|
|
AU2006311475A1
(en)
|
2005-11-08 |
2007-05-18 |
Medarex, Inc. |
TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
|
|
CN101432302A
(zh)
|
2005-11-30 |
2009-05-13 |
艾博特公司 |
抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
|
|
CA2631195C
(en)
|
2005-11-30 |
2016-04-05 |
Abbott Laboratories |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
|
WO2007067959A2
(en)
|
2005-12-07 |
2007-06-14 |
Medarex, Inc. |
Ctla-4 antibody dosage escalation regimens
|
|
EP1997887B1
(en)
|
2006-03-03 |
2013-09-04 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of cell surface functional molecule
|
|
CA2646671A1
(en)
|
2006-03-30 |
2007-11-01 |
University Of California |
Methods and compositions for localized secretion of anti-ctla-4 antibodies
|
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
KR20090029184A
(ko)
|
2006-04-07 |
2009-03-20 |
더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
항체 조성물 및 신생물성 질병의 치료 방법
|
|
EP2054444B1
(en)
|
2006-08-04 |
2016-11-02 |
MedImmune Limited |
Antibodies to erbb2
|
|
KR101544108B1
(ko)
|
2006-09-08 |
2015-08-13 |
애브비 바하마스 리미티드 |
인터루킨-13 결합 단백질
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
CA2680549A1
(en)
|
2007-03-12 |
2008-09-18 |
Alan D. D'andrea |
Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
|
|
CA2682927A1
(en)
|
2007-04-02 |
2008-10-16 |
Amgen Fremont Inc. |
Anti-ige antibodies
|
|
EP3124046B1
(en)
|
2007-07-12 |
2019-12-25 |
GITR, Inc. |
Combination therapies employing gitr binding molecules
|
|
NZ584848A
(en)
|
2007-09-28 |
2012-09-28 |
Intrexon Corp |
Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
|
|
WO2009058564A2
(en)
|
2007-11-01 |
2009-05-07 |
Maxygen, Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
SI2851374T1
(sl)
|
2007-12-14 |
2017-08-31 |
Bristol-Myers Squibb Company |
Vezavne molekule k humanemu ox40 receptorju
|
|
CN101909693A
(zh)
|
2008-01-08 |
2010-12-08 |
百时美施贵宝公司 |
用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
|
|
WO2009100140A1
(en)
*
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
WO2009136382A2
(en)
|
2008-05-09 |
2009-11-12 |
Abbott Gmbh & Co. Kg |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
|
MX2010013239A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
UY31861A
(es)
|
2008-06-03 |
2010-01-05 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
RU2559525C2
(ru)
|
2008-07-08 |
2015-08-10 |
Эббви Инк |
Белки, связывающие простагландин е2, и их применение
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
SG10201701323TA
(en)
|
2008-08-18 |
2017-04-27 |
Amgen Fremont Inc |
Antibodies to ccr2
|
|
KR101012267B1
(ko)
*
|
2008-08-29 |
2011-02-08 |
주식회사 세이프로드 |
파손이 방지되는 차선규제봉 및 차선규제봉 시공방법
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
ES2726702T3
(es)
|
2009-01-15 |
2019-10-08 |
Adaptive Biotechnologies Corp |
Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
|
|
NZ611324A
(en)
|
2009-03-05 |
2015-02-27 |
Abbvie Inc |
Il-17 binding proteins
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
SI2769737T1
(sl)
|
2009-07-20 |
2017-06-30 |
Bristol-Myers Squibb Company |
Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni
|
|
PE20121647A1
(es)
|
2009-08-29 |
2012-12-31 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
|
UY32870A
(es)
|
2009-09-01 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
CA2777226A1
(en)
|
2009-10-12 |
2011-04-21 |
Pfizer Inc. |
Cancer treatment
|
|
RU2012119756A
(ru)
|
2009-10-15 |
2013-11-20 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
WO2011070045A1
(en)
|
2009-12-08 |
2011-06-16 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
WO2011109298A2
(en)
|
2010-03-02 |
2011-09-09 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
UY33386A
(es)
|
2010-05-14 |
2011-12-30 |
Abbott Laboratoires |
Proteínas de unión a il-1
|
|
WO2011146382A1
(en)
|
2010-05-17 |
2011-11-24 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
|
SI3333188T1
(sl)
|
2010-08-19 |
2022-04-29 |
Zoetis Belgium S.A. |
Protitelesa proti NGF in njihova uporaba
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
EP2646552B1
(en)
*
|
2010-12-02 |
2017-07-05 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for ctla-4
|
|
WO2012082073A1
(en)
|
2010-12-14 |
2012-06-21 |
National University Of Singapore |
Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
|
|
JP6009455B2
(ja)
|
2010-12-21 |
2016-10-19 |
アッヴィ・インコーポレイテッド |
Ｉｌ−１アルファおよびベータ二重特異的二重可変ドメイン免疫グロブリンおよびその使用
|
|
WO2012088094A2
(en)
|
2010-12-21 |
2012-06-28 |
Abbott Laboratories |
Il-1 binding proteins
|
|
GB201103955D0
(en)
*
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
|
JP2014520847A
(ja)
|
2011-07-13 |
2014-08-25 |
アッヴィ・インコーポレイテッド |
抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物
|
|
WO2013013029A1
(en)
|
2011-07-19 |
2013-01-24 |
The Board Of Trustees Of The University Of Illinois |
Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
|
|
MX359314B
(es)
|
2011-08-30 |
2018-09-25 |
Astex Pharmaceuticals Inc Star |
Formulaciones derivadas de decitabina.
|
|
EP2771360A1
(en)
|
2011-10-24 |
2014-09-03 |
AbbVie Inc. |
Immunobinders directed against sclerostin
|
|
AU2012328921B2
(en)
|
2011-10-24 |
2017-05-11 |
Abbvie Inc. |
Immunobinders directed against TNF
|
|
CA2856149A1
(en)
|
2011-11-08 |
2013-05-16 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-m-csf antibodies
|
|
CA2855840C
(en)
|
2011-12-14 |
2023-08-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
MX356933B
(es)
|
2011-12-14 |
2018-06-20 |
Abbvie Deutschland |
Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
|
|
MX2014008101A
(es)
|
2011-12-30 |
2014-09-25 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
|
|
NZ714482A
(en)
|
2012-01-27 |
2017-08-25 |
Abbvie Inc |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
|
WO2013142796A2
(en)
|
2012-03-23 |
2013-09-26 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla4 antibodies
|
|
EP2836514A4
(en)
|
2012-04-13 |
2015-12-30 |
Childrens Medical Center |
TIKI INHIBITORS
|
|
PE20142406A1
(es)
|
2012-05-04 |
2015-01-23 |
Pfizer |
Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
|
|
US20150118244A1
(en)
|
2012-05-10 |
2015-04-30 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
|
SG11201407190TA
(en)
|
2012-05-15 |
2014-12-30 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
CA2875783C
(en)
|
2012-06-06 |
2018-12-11 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
AR091755A1
(es)
|
2012-07-12 |
2015-02-25 |
Abbvie Inc |
Proteinas de union a il-1
|
|
US8968742B2
(en)
*
|
2012-08-23 |
2015-03-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
|
|
TW201811825A
(zh)
|
2012-11-01 |
2018-04-01 |
美商艾伯維有限公司 |
抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
|
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
|
CN105025884B
(zh)
|
2013-03-01 |
2019-08-20 |
阿斯泰克斯制药公司 |
药物组合
|
|
CN105452292A
(zh)
|
2013-03-14 |
2016-03-30 |
帕卡什·吉尔 |
使用结合细胞表面grp78的抗体进行癌症治疗
|
|
JP6739329B2
(ja)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
Ｈｃｖコア脂質結合ドメインモノクローナル抗体
|
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
|
CA2906407A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
|
|
TW201512219A
(zh)
|
2013-03-15 |
2015-04-01 |
Abbvie Inc |
針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
EP3003372B1
(en)
|
2013-06-07 |
2019-10-09 |
Duke University |
Inhibitors of complement factor h
|
|
MX2016001555A
(es)
|
2013-08-08 |
2016-08-03 |
Cytune Pharma |
Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
|
|
EP3030262B1
(en)
|
2013-08-08 |
2019-10-09 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
ES2728578T3
(es)
|
2013-09-20 |
2019-10-25 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
|
|
KR102196884B1
(ko)
|
2013-11-01 |
2020-12-30 |
화이자 인코포레이티드 |
전립선-연관 항원의 발현을 위한 벡터
|
|
JP2016540042A
(ja)
|
2013-11-05 |
2016-12-22 |
コグネート バイオサービシズ， インコーポレイテッド |
がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
|
|
US20160264670A1
(en)
|
2013-11-06 |
2016-09-15 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
CA2936611A1
(en)
|
2014-01-13 |
2015-07-16 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
EA201692458A1
(ru)
|
2014-05-28 |
2017-06-30 |
Агенус Инк. |
Анти-gitr антитела и способы их применения
|
|
KR102204937B1
(ko)
|
2014-06-06 |
2021-01-18 |
브리스톨-마이어스 스큅 컴퍼니 |
글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
|
|
CN105296433B
(zh)
*
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
|
ES2804826T3
(es)
|
2014-09-16 |
2021-02-09 |
Synermore Biologics Co Ltd |
Anticuerpo anti-EGFR y usos del mismo
|
|
EP4029508A1
(en)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
|
DK3207130T3
(da)
|
2014-10-14 |
2019-11-11 |
Halozyme Inc |
Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
|
|
WO2016070769A1
(zh)
*
|
2014-11-04 |
2016-05-12 |
北京韩美药品有限公司 |
同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
|
|
CN105597090B
(zh)
*
|
2014-11-14 |
2022-08-23 |
中国科学院上海营养与健康研究所 |
一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
|
|
DK3221346T3
(da)
|
2014-11-21 |
2020-10-12 |
Bristol Myers Squibb Co |
Antistoffer omfattende modificerede konstante områder af tungkæden
|
|
CA2968357A1
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
|
EP3227335A1
(en)
|
2014-12-04 |
2017-10-11 |
Bristol-Myers Squibb Company |
Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
|
|
CN104387453A
(zh)
*
|
2014-12-08 |
2015-03-04 |
深圳市同康生物医药有限公司 |
树突状细胞靶向肽及编码基因及应用
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
MY187045A
(en)
|
2014-12-23 |
2021-08-27 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
AU2015374385B2
(en)
|
2014-12-31 |
2020-08-06 |
Checkmate Pharmaceuticals, Inc. |
Combination tumor immunotherapy
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
JP6917902B2
(ja)
*
|
2015-02-13 |
2021-08-11 |
ソレント・セラピューティクス・インコーポレイテッド |
Ｃｔｌａ４に結合する抗体医薬
|
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
US10376535B2
(en)
|
2015-03-26 |
2019-08-13 |
University Of Rochester |
Therapy for malignant disease
|
|
WO2016163489A1
(ja)
|
2015-04-07 |
2016-10-13 |
日本電気株式会社 |
医薬
|
|
EP4005386A1
(en)
|
2015-05-06 |
2022-06-01 |
SNIPR Technologies Limited |
Altering microbial populations & modifying microbiota
|
|
US10881733B2
(en)
|
2015-05-22 |
2021-01-05 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
|
SI3303395T1
(sl)
|
2015-05-29 |
2020-03-31 |
Abbvie Inc. |
Protitelesa proti CD40 in njihove uporabe
|
|
ES2936317T3
(es)
|
2015-05-29 |
2023-03-16 |
Bristol Myers Squibb Co |
Anticuerpos contra OX40 y usos de los mismos
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
MX2017015765A
(es)
|
2015-06-29 |
2018-04-13 |
Squibb Bristol Myers Co |
Regimenes de dosificacion inmunoterapeutica que comprenden pomalidomida y un anticuerpo anti-cs1 para el tratamiento de cancer.
|
|
BR112017028353A2
(pt)
|
2015-06-29 |
2018-09-04 |
The Rockfeller University |
anticorpos para cd40 com atividade agonista melhorada
|
|
RU2723590C2
(ru)
|
2015-07-02 |
2020-06-16 |
Оцука Фармасьютикал Ко., Лтд. |
Лиофилизированные фармацевтические композиции
|
|
AU2016291817A1
(en)
|
2015-07-16 |
2018-02-22 |
Biolinerx Ltd. |
Compositions and methods for treating cancer
|
|
JP7032311B2
(ja)
|
2015-07-16 |
2022-03-08 |
バイオエクセル セラピューティクス，インコーポレイテッド |
免疫調節を使用してがんを処置するための新規手法
|
|
EP3331917A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
|
LT3370733T
(lt)
|
2015-11-02 |
2021-10-25 |
Board Of Regents, The University Of Texas System |
Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
|
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
|
JP2018532810A
(ja)
|
2015-11-07 |
2018-11-08 |
マルチビア インコーポレイテッド |
がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
|
|
EP3377532B1
(en)
|
2015-11-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
EP3383430A4
(en)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
ANTIBODIES AND METHOD FOR USE THEREOF
|
|
UA125611C2
(uk)
|
2015-12-14 |
2022-05-04 |
Макродженікс, Інк. |
Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
|
|
US20190241658A1
(en)
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
|
WO2017152085A1
(en)
|
2016-03-04 |
2017-09-08 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス，インコーポレイティド |
ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
|
|
PL3429618T3
(pl)
|
2016-03-16 |
2024-07-01 |
Amal Therapeutics Sa |
Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
|
|
CN109195990A
(zh)
|
2016-03-30 |
2019-01-11 |
Musc研究发展基金会 |
通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
|
|
EP3436066A1
(en)
|
2016-04-01 |
2019-02-06 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
US20200377606A1
(en)
|
2016-04-18 |
2020-12-03 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
IL262643B2
(en)
|
2016-04-29 |
2023-09-01 |
Univ Texas |
Targeted measurement of hormone receptor-associated transcriptional activity
|
|
WO2017192874A1
(en)
|
2016-05-04 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CN109641044A
(zh)
|
2016-05-30 |
2019-04-16 |
吉奥瓦科斯公司 |
用于产生对乙型肝炎病毒的免疫应答的组合物和方法
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
KR102531889B1
(ko)
|
2016-06-20 |
2023-05-17 |
키맵 리미티드 |
항-pd-l1 및 il-2 사이토카인
|
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
CN109757103B
(zh)
|
2016-07-14 |
2024-01-02 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
KR20190057345A
(ko)
|
2016-09-21 |
2019-05-28 |
아말 테라퓨틱스 에스에이 |
암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
|
|
US11395838B2
(en)
|
2016-09-27 |
2022-07-26 |
Board Of Regents, The University Of Texas System |
Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
|
|
MX2019003473A
(es)
|
2016-10-03 |
2019-10-15 |
Abbott Lab |
Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes.
|
|
CN110035773B
(zh)
*
|
2016-10-10 |
2023-06-02 |
中美冠科生物技术（太仓）有限公司 |
新型抗ctla4抗体
|
|
ES2972560T3
(es)
|
2016-10-11 |
2024-06-13 |
Nec Corp |
Medicamento que comprende un agonista de receptores tipo Toll, proteína LAG-3, un péptido derivado de HSP70 y un péptido derivado de GPC3
|
|
CA3040458A1
(en)
|
2016-10-12 |
2018-04-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions for tusc2 immunotherapy
|
|
US20190315865A1
(en)
|
2016-10-28 |
2019-10-17 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
|
JP2019534044A
(ja)
*
|
2016-11-08 |
2019-11-28 |
クイル ピュージェット サウンド バイオセラピューティクス コーポレーション |
抗ｐｄ１および抗ｃｔｌａ４抗体
|
|
CA3043356A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
WO2018098401A1
(en)
|
2016-11-23 |
2018-05-31 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
BR112019011350A2
(pt)
|
2016-12-01 |
2019-10-22 |
Glaxosmithkline Ip Dev Ltd |
terapia de combinação
|
|
KR20190090822A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 요법
|
|
US11273155B2
(en)
|
2016-12-12 |
2022-03-15 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
US11319372B2
(en)
*
|
2017-02-21 |
2022-05-03 |
Remd Biotherapeutics, Inc. |
Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
|
|
CN110612447B
(zh)
|
2017-02-24 |
2024-02-06 |
德克萨斯州立大学董事会 |
用于检测早期胰腺癌的测定
|
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體－藥物結合物之組合療法
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
EP3596469A1
(en)
|
2017-03-12 |
2020-01-22 |
Yeda Research and Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018175942A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
|
EP3601355A1
(en)
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
CA3053409A1
(en)
|
2017-04-15 |
2018-10-18 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
|
US11760777B2
(en)
|
2017-04-26 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
|
BR112019022476A2
(pt)
|
2017-04-28 |
2020-05-12 |
Abbott Laboratories |
Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
IL270743B2
(en)
|
2017-05-19 |
2024-09-01 |
Wuxi Biologics Shanghai Co Ltd |
Monoclonal antibodies to lymphocyte-associated protein - Tcytotoxic 4 (CTLA-4), preparations containing them and their uses
|
|
CN108948194B
(zh)
*
|
2017-05-19 |
2023-02-17 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
|
EP3630833A1
(en)
|
2017-05-25 |
2020-04-08 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
US10866251B2
(en)
|
2017-05-25 |
2020-12-15 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
|
EP4245375A3
(en)
|
2017-05-30 |
2023-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
CN110678200B
(zh)
|
2017-05-30 |
2024-05-17 |
百时美施贵宝公司 |
包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
|
|
HRP20231457T1
(hr)
|
2017-05-30 |
2024-05-10 |
Bristol-Myers Squibb Company |
Liječenje lag-3-pozitivnih tumora
|
|
BR112019025387A2
(pt)
|
2017-05-30 |
2020-07-07 |
Abbott Laboratories |
métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces
|
|
CN110719799A
(zh)
|
2017-06-09 |
2020-01-21 |
俄勒冈州普罗维登斯健康与服务部 |
Cd39和cd103在鉴定用于癌症治疗的人肿瘤反应性t细胞中的应用
|
|
JP7454945B2
(ja)
|
2017-07-03 |
2024-03-25 |
アボット・ラボラトリーズ |
血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
|
|
CR20200076A
(es)
|
2017-07-14 |
2020-06-10 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
|
NZ761519A
(en)
|
2017-07-14 |
2023-07-28 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
KR20200035438A
(ko)
|
2017-08-03 |
2020-04-03 |
오쓰까 세이야꾸 가부시키가이샤 |
약물 화합물 및 이의 정제 방법
|
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
|
KR20200064132A
(ko)
|
2017-10-15 |
2020-06-05 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
JP2021501801A
(ja)
|
2017-11-01 |
2021-01-21 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
癌の処置に用いるための免疫刺激アゴニスト抗体
|
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN108003238B
(zh)
*
|
2017-11-30 |
2021-02-02 |
常州费洛斯药业科技有限公司 |
一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
|
|
US11022617B2
(en)
|
2017-12-09 |
2021-06-01 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
|
|
CN110892266A
(zh)
|
2017-12-09 |
2020-03-17 |
雅培实验室 |
使用gfap和uch-l1的组合辅助诊断和评价人类受试者中创伤性脑损伤的方法
|
|
KR102476887B1
(ko)
*
|
2017-12-20 |
2022-12-13 |
하버 바이오메드 (상하이) 컴퍼니 리미티드 |
Ctla-4에 결합하는 항체 및 이의 용도
|
|
WO2019126691A1
(en)
|
2017-12-21 |
2019-06-27 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
WO2019133747A1
(en)
|
2017-12-27 |
2019-07-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
US20220089720A1
(en)
|
2018-01-12 |
2022-03-24 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
CA3088542A1
(en)
|
2018-01-22 |
2019-07-25 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
RU2020129265A
(ru)
|
2018-03-12 |
2022-04-12 |
ЗОИТИС СЕРВИСЕЗ ЭлЭлСи |
Антитела против ngf и связанные с ними способы
|
|
US20210030703A1
(en)
|
2018-03-12 |
2021-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
|
EP3768721A4
(en)
*
|
2018-03-19 |
2021-12-29 |
Wuxi Biologics Ireland Limited. |
Novel anti-ctla-4 antibody polypeptide
|
|
AU2019322487B2
(en)
|
2018-03-19 |
2024-04-18 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
|
|
PE20210290A1
(es)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
EP3773685A1
(en)
|
2018-03-25 |
2021-02-17 |
SNIPR Biome ApS. |
Treating & preventing microbial infections
|
|
EP3773551A4
(en)
|
2018-03-27 |
2022-03-23 |
Board of Regents, The University of Texas System |
COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING HER2 EXON 19 MUTATIONS
|
|
WO2019191676A1
(en)
|
2018-03-30 |
2019-10-03 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
AU2019251421A1
(en)
|
2018-04-09 |
2020-10-29 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
|
US11524991B2
(en)
|
2018-04-18 |
2022-12-13 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
CA3097865A1
(en)
|
2018-04-25 |
2019-10-31 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
WO2019232319A1
(en)
|
2018-05-31 |
2019-12-05 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting cd73
|
|
PE20211604A1
(es)
|
2018-07-09 |
2021-08-23 |
Five Prime Therapeutics Inc |
Anticuerpos de union a ilt4
|
|
JP7340591B2
(ja)
|
2018-07-11 |
2023-09-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
|
KR20210031722A
(ko)
|
2018-07-11 |
2021-03-22 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
MX2021000745A
(es)
|
2018-07-20 |
2021-03-26 |
Surface Oncology Inc |
Composiciones anti-cd112r y metodos.
|
|
US20210308123A1
(en)
|
2018-08-16 |
2021-10-07 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
US11572360B2
(en)
|
2018-08-16 |
2023-02-07 |
Innate Tumor Immunity, Inc. |
Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
|
|
ES2974964T3
(es)
|
2018-08-16 |
2024-07-02 |
Innate Tumor Immunity Inc |
Moduladores de NLRP3 derivados de imidazo[4,5-c]quinolina
|
|
EP3617230A1
(en)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Novel antibodies and nucleotide sequences, and uses thereof
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
WO2020057645A1
(zh)
|
2018-09-21 |
2020-03-26 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
CN112105633B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
WO2020070053A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
|
WO2020077276A2
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
|
US20230021500A1
(en)
|
2018-10-29 |
2023-01-26 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
PE20211284A1
(es)
|
2018-11-16 |
2021-07-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-nkg2a y usos de los mismos
|
|
CN113286813A
(zh)
|
2018-11-19 |
2021-08-20 |
得克萨斯大学体系董事会 |
用于car和tcr转导的模块化多顺反子载体
|
|
US20220031749A1
(en)
|
2018-11-28 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
ES2971964T3
(es)
|
2018-11-28 |
2024-06-10 |
Inst Nat Sante Rech Med |
Métodos y kit para someter a ensayo el potencial lítico de células efectoras inmunitarias
|
|
MX2021006393A
(es)
|
2018-11-29 |
2021-10-13 |
Univ Texas |
Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
|
|
US20220018835A1
(en)
|
2018-12-07 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
BR112021011224A2
(pt)
|
2018-12-11 |
2021-08-24 |
Theravance Biopharma R&D Ip, Llc |
Inibidores de alk5
|
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
SG11202106898VA
(en)
|
2018-12-28 |
2021-07-29 |
Transgene Sa |
M2-defective poxvirus
|
|
WO2020150116A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
|
CN113301963A
(zh)
|
2019-01-14 |
2021-08-24 |
先天肿瘤免疫公司 |
用于治疗癌症的作为nlrp3调节剂的取代的喹唑啉类
|
|
JP7335341B2
(ja)
|
2019-01-14 |
2023-08-29 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
EP3911417B1
(en)
|
2019-01-14 |
2022-10-26 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators , for use in the treatment of cancer
|
|
CA3126741A1
(en)
|
2019-01-15 |
2020-07-23 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
JP2022524545A
(ja)
|
2019-03-13 |
2022-05-06 |
イーザアールエヌーエー イムノセラピーズ エンヴェー |
ｍＲＮＡワクチン
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
KR20210146349A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
US20220177978A1
(en)
|
2019-04-02 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
WO2020212484A1
(en)
|
2019-04-17 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
EP3966315A1
(en)
|
2019-05-09 |
2022-03-16 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
|
CN114096240A
(zh)
|
2019-05-17 |
2022-02-25 |
癌症预防制药股份有限公司 |
用于治疗家族性腺瘤性息肉病的方法
|
|
EP3976832A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
KR20220016156A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
CA3144533A1
(en)
|
2019-06-03 |
2020-12-10 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
|
CN114173822A
(zh)
|
2019-06-03 |
2022-03-11 |
芝加哥大学 |
用胶原结合药物载体治疗癌症的方法和组合物
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
CN114340659B
(zh)
|
2019-06-27 |
2024-06-25 |
伊泽阿恩埃免疫疗法股份有限公司 |
联合治疗
|
|
EP3994270A1
(en)
|
2019-07-02 |
2022-05-11 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
CN114174336A
(zh)
|
2019-07-15 |
2022-03-11 |
英特维特国际股份有限公司 |
针对人和犬ctla-4的犬源化抗体
|
|
US20220251208A1
(en)
|
2019-07-15 |
2022-08-11 |
Intervet Inc. |
Caninized Antibodies Against Canine CTLA-4
|
|
JPWO2021024742A1
(es)
*
|
2019-08-06 |
2021-02-11 |
|
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
US20220380314A1
(en)
|
2019-09-17 |
2022-12-01 |
Bial - R&D Investments, S.A. |
Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
|
|
JP2022548747A
(ja)
|
2019-09-17 |
2022-11-21 |
バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ |
酸性セラミダーゼ阻害剤としての置換されたｎ－複素環式カルボキサミド及び医薬としてのその使用
|
|
AU2020349516A1
(en)
|
2019-09-17 |
2022-03-17 |
Bial-R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
|
CN114729043A
(zh)
|
2019-09-19 |
2022-07-08 |
百时美施贵宝公司 |
在酸性pH下结合至VISTA的抗体
|
|
US20220348653A1
(en)
|
2019-09-22 |
2022-11-03 |
Bristol-Myers Squibb Company |
Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
|
|
MX2022003719A
(es)
|
2019-09-25 |
2022-04-26 |
Surface Oncology Inc |
Anticuerpos anti-il-27 y sus usos.
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
EP4037700A2
(en)
|
2019-10-03 |
2022-08-10 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
KR20220088425A
(ko)
|
2019-10-25 |
2022-06-27 |
다이이찌 산쿄 가부시키가이샤 |
항 garp 항체와 면역 조절제의 조합
|
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
AU2020380384A1
(en)
|
2019-11-08 |
2022-05-26 |
Bristol-Myers Squibb Company |
LAG-3 antagonist therapy for melanoma
|
|
CA3160307A1
(en)
|
2019-11-22 |
2021-05-27 |
Theravance Biopharma R&D Ip, Llc |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
|
WO2021106978A1
(ja)
|
2019-11-27 |
2021-06-03 |
サイトリミック株式会社 |
医薬組成物
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
AU2020407130A1
(en)
|
2019-12-19 |
2022-06-16 |
Bristol-Myers Squibb Company |
Combinations of DGK inhibitors and checkpoint antagonists
|
|
KR102645629B1
(ko)
|
2019-12-27 |
2024-03-07 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체 및 그의 사용
|
|
AU2021206202A1
(en)
|
2020-01-07 |
2022-06-30 |
Board Of Regents, The University Of Texas System |
Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
CN115244052A
(zh)
|
2020-01-10 |
2022-10-25 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
CN115397848A
(zh)
|
2020-02-05 |
2022-11-25 |
拉利玛生物医药公司 |
Tat肽结合蛋白及其用途
|
|
EP4100426A1
(en)
|
2020-02-06 |
2022-12-14 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
WO2021170750A1
(en)
|
2020-02-28 |
2021-09-02 |
Orega Biotech |
Combination therapies based on ctla4 and il-17b inhibitors
|
|
US20230085724A1
(en)
|
2020-03-05 |
2023-03-23 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
|
WO2021183428A1
(en)
|
2020-03-09 |
2021-09-16 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
CA3172449A1
(en)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
EP4126824A1
(en)
|
2020-03-31 |
2023-02-08 |
Theravance Biopharma R&D IP, LLC |
Substituted pyrimidines and methods of use
|
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
|
CA3175499A1
(en)
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
|
IL297442A
(en)
|
2020-04-22 |
2022-12-01 |
Iovance Biotherapeutics Inc |
Systems and methods for coordinating production of cells for patient-specific immunotherapy
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
AU2021275239A1
(en)
|
2020-05-21 |
2022-12-15 |
Board Of Regents, The University Of Texas System |
T cell receptors with VGLL1 specificity and uses thereof
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
AU2021285044A1
(en)
|
2020-06-03 |
2022-12-08 |
Institute For Research In Biomedicine |
Combination of an ATP-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
|
CN115803062A
(zh)
|
2020-06-03 |
2023-03-14 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
|
EP4165041A1
(en)
|
2020-06-10 |
2023-04-19 |
Theravance Biopharma R&D IP, LLC |
Naphthyridine derivatives useful as alk5 inhibitors
|
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
JP2023531537A
(ja)
|
2020-06-30 |
2023-07-24 |
メンドゥス・ベスローテン・フェンノートシャップ |
卵巣癌ワクチンでの白血病由来細胞の使用
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
EP4178611A1
(en)
|
2020-07-07 |
2023-05-17 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
CA3184940A1
(en)
|
2020-07-07 |
2022-01-13 |
Jennifer Donglan WU |
Mic antibodies and binding agents and methods of using the same
|
|
JP2023534987A
(ja)
|
2020-07-24 |
2023-08-15 |
アムジエン・インコーポレーテツド |
Ｓａｒｓ－ｃｏｖ２スパイクタンパク質に由来する免疫原
|
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
|
CN112359052B
(zh)
*
|
2020-08-20 |
2023-01-03 |
山东兴瑞生物科技有限公司 |
抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
|
|
KR20230058442A
(ko)
|
2020-08-28 |
2023-05-03 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 lag-3 길항제 요법
|
|
WO2022047412A1
(en)
|
2020-08-31 |
2022-03-03 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
JP2023548051A
(ja)
|
2020-10-23 |
2023-11-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
肺がんのためのｌａｇ－３アンタゴニスト療法
|
|
EP4243839A1
(en)
|
2020-11-13 |
2023-09-20 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
US20220162288A1
(en)
|
2020-11-25 |
2022-05-26 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2022119841A1
(en)
|
2020-12-01 |
2022-06-09 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
CA3201219A1
(en)
|
2020-12-04 |
2022-06-09 |
Mir Ali |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
CN116601170A
(zh)
*
|
2020-12-10 |
2023-08-15 |
上海药明生物技术有限公司 |
抗p-钙粘蛋白抗体及其用途
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
CA3206125A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
US20240076391A1
(en)
|
2020-12-24 |
2024-03-07 |
Oncurious Nv |
Human ccr8 binders
|
|
CA3206124A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Non-blocking human ccr8 binders
|
|
MX2023007650A
(es)
|
2020-12-28 |
2023-09-11 |
Bristol Myers Squibb Co |
Metodos de tratamiento de tumores.
|
|
JP2024503265A
(ja)
|
2020-12-28 |
2024-01-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗体組成物およびその使用の方法
|
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
|
CN117529338A
(zh)
|
2021-01-19 |
2024-02-06 |
威廉马歇莱思大学 |
多肽的骨特异性递送
|
|
AU2022211682A1
(en)
|
2021-01-22 |
2023-08-03 |
Mendus B.V. |
Methods of tumor vaccination
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
|
TW202304524A
(zh)
|
2021-04-10 |
2023-02-01 |
美商普方生物製藥美國公司 |
Folr1結合劑、其結合物及使用方法
|
|
EP4079311A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Ｃｄ７０結合劑、其結合物及其使用方法
|
|
EP4341699A1
(en)
|
2021-05-18 |
2024-03-27 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
US20240118279A1
(en)
|
2021-06-14 |
2024-04-11 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
|
CN117616123A
(zh)
|
2021-06-25 |
2024-02-27 |
中外制药株式会社 |
抗ctla-4抗体
|
|
BR112023023480A2
(pt)
|
2021-06-25 |
2024-01-30 |
Chugai Pharmaceutical Co Ltd |
Uso de anticorpo anti-ctla-4
|
|
EP4367269A1
(en)
|
2021-07-05 |
2024-05-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
AU2022312698A1
(en)
|
2021-07-13 |
2024-01-25 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
AU2022324040A1
(en)
|
2021-08-04 |
2024-02-22 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
CN118284623A
(zh)
|
2021-08-23 |
2024-07-02 |
伊莫尼塔斯治疗公司 |
抗cd161抗体及其用途
|
|
CA3230038A1
(en)
|
2021-08-31 |
2023-03-09 |
Hongwei Zhang |
Methods and systems of diagnosing brain injury
|
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
|
IL311790A
(en)
|
2021-10-05 |
2024-05-01 |
Chang Hao Ming |
Natural killer cells and methods of their use
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
IL309227A
(en)
|
2021-10-29 |
2024-02-01 |
Bristol Myers Squibb Co |
LAG-3 antagonist therapy for hematological cancer
|
|
EP4433096A1
(en)
|
2021-11-19 |
2024-09-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
AU2022396272A1
(en)
*
|
2021-11-24 |
2024-06-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
|
CA3240822A1
(en)
|
2021-12-17 |
2023-06-22 |
Tony Lee |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
|
TW202332687A
(zh)
|
2021-12-23 |
2023-08-16 |
比利時商ｅＴｈｅＲＮＡ免疫治療公司 |
免疫刺激性mrna組成物及其用途
|
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
|
IL314050A
(en)
|
2022-01-26 |
2024-09-01 |
Bristol Myers Squibb Co |
Combined treatment method for hepatocellular carcinoma
|
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
|
AU2023226078A1
(en)
|
2022-02-25 |
2024-08-22 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma.
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
TW202423482A
(zh)
|
2022-06-08 |
2024-06-16 |
美商泰德治療公司 |
可電離陽離子脂質和脂質奈米顆粒、及其合成方法和用途
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
|
WO2024003353A1
(en)
|
2022-07-01 |
2024-01-04 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
TW202412859A
(zh)
|
2022-07-28 |
2024-04-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及雙特異性檢查點抑制劑之組合
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
WO2024137776A1
(en)
|
2022-12-21 |
2024-06-27 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|